Immix Biopharma, Inc. (IMMX)
IMMXNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$8.55
+0.2000 (+2.40%) today
Regular session, Nov 11, 1:58 PM ET
- Market cap
- $708.82m
- P/E
- –
- EPS, last 4 quarters
- $-0.8800
- Dividend yield
- –
- Day range
- $8.30 to $8.69
- 52-week range
- $3.16 to $15.10
- Average volume
- 1.45m
- Previous close
- $8.35
Analysts
6 coveringBuy6 buy, 0 hold, 0 sell
Targets a year out average $25.40, +197.1% from here
Earnings
next estimate $-0.1800Next report Nov 13, 2026
Sep 2025
-26.3%
Dec 2025
-75.0%
Mar 2026
+14.3%
Jun 2026
-5.9%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$7.66m | -$10.89m | -$10.80m | -$12.46m |
| Net income | -$7.59m | -$10.69m | -$10.09m | -$11.56m |
News
8 latest- Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?Zacks · Oct 27, 2026
- Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis StudyMarketBeat · Oct 4, 2026
- Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data RTTNews · Oct 2, 2026
- Immix Biopharma Consensus Price Target Increased by 10.16% to $25.04Fintel · Oct 2, 2026
- ImmixBio Reports 89% CR Rate, Potential 98% With NXC-201 In AL Amyloidosis RTTNews · Sep 29, 2026
- Immix Biopharma's NXC-201 Shows 89% Complete Response Rate In AL Amyloidosis RTTNews · Sep 29, 2026
- All You Need to Know About Immix Biopharma (IMMX) Rating Upgrade to BuyZacks · Jun 24, 2026
- Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a BetZacks · Jun 18, 2026
The company
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that's supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a proprietary CD3, CD8 hinge and binder 'digital filter' designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a potentially registrational design.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- immixbio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.